Transforming Patient Recruitment: myTomorrows Introduces Next-Generation AI Platform for Precision Trial Matching

With the goal of streamlining industry-wide clinical trial recruitment and improving patient outcomes, myTomorrows unveils its next major AI-powered technological advancement.

AMSTERDAM, Feb. 6, 2025 /PRNewswire/ -- myTomorrows, a global health technology company connecting patients and physicians with all possible pre-approval treatment options, today announced the launch of its next-generation AI platform. Designed to streamline clinical trial recruitment, the platform supercharges how physicians search, pre-screen, and refer patients — helping trial sponsors accelerate enrollment, enhance diversity, and optimize operations. At the core of this innovation is myTomorrows' best-in-class AI pre-screening tool, which automates eligibility checking with superhuman precision. Updates to the platform now mean that myTomorrows can offer 98% accuracy for fully automated trial eligibility matching, significantly outperforming both industry benchmarks and users with a medical background.

The rise in disease subtypes has led to a growing number of clinical trials and increasingly complex eligibility criteria. With over 500,000 clinical trials registered globally and more than 8,000 drugs in development, navigating this landscape is overwhelming and time consuming for treating physicians. As a result, trial sponsors and sites experience limited trial visibility, making it harder to meet recruitment and retention goals.

To tackle these challenges head-on, the myTomorrows platform takes a cutting-edge, multi-stakeholder approach designed to simplify processes for patients, physicians, and sites—thereby offering a first-of-its-kind solution to optimize patient recruitment at scale.  

The platform sources trials from multiple global registries, including ClinicalTrials.gov, EudraCT and ISRCTN, and intelligently matches patient medical data against each trial's inclusion and exclusion criteria. With an impressive 98% accuracy in determining patient eligibility, it automatically classifies trials as eligible or ineligible, allowing physicians to identify suitable trial options in minutes instead of hours. Built with security and compliance at its core, the platform is ISO 27001-certified, GPDR and HIPAA compliant, allowing direct input or integration of (un)structured medical data from Electronic Health Records (EHRs).

The AI pre-screening results are securely stored on the platform, enabling physicians to make quick direct-to-site referrals with confidence. For trial sites, referral communication and management are simplified, giving them access to highly qualified, pre-screened patients through an intuitive, end-to-end compliant platform. To further inform decision-making, the platform also includes a 'latest clinical trial data' feature, offering insights into the mechanism of action, efficacy, and safety profile of the investigational pre-approval treatment.

"Physicians are committed to providing the best care for their patients, yet many lack the necessary time to navigate the often confusing and complicated process of identifying suitable clinical trials," said Michel van Harten, MD, CEO of myTomorrows. "This gap results in increased workloads for both physicians and site staff, a reduced likelihood of successful screening and enrollment, and missed opportunities for patients. Our next-generation AI platform will lower barriers for physicians by streamlining the clinical trial search, pre-screening and referral process – all in one secure place. Built as a strong foundation for future agentic AI applications, we're taking a bold step in leading the future of clinical trial access."

In a series of internal performance tests, the AI pre-screening tool was tested against users with medically trained backgrounds and the Harvard n2c2 benchmark. Across 9 disease areas and 490 trials, results showed the AI achieved 98% accuracy in checking patient eligibility and matching to relevant trials, outperforming both the test group and benchmark.

With AI already shaping the future of the BioPharma industry, myTomorrows' next-generation AI platform is set to transform the field of clinical research — empowering physicians to navigate trial options with greater precision, expanding treatment access for broader patient populations, and helping sponsors advance diversity and equity in trial participation.

The first glimpse of this technology will be unveiled on stage at the SCOPE Summit in Orlando, Florida, on 6 February, 2025. As the leading event for clinical operations executives, SCOPE is dedicated to driving innovation in clinical trials. Bringing together over 1,200 organizations from 30 countries, the summit serves as the premier platform for showcasing the latest advancements in clinical research. myTomorrows will demonstrate how its unique offering — powered by state-of-the-art LLMs — enables physicians to efficiently identify the most suitable trials for their patients and instantly refer high-quality leads to participating trial sites.

The platform will soon also be available to enterprises, including institutions, hospitals, trial sites, Clinical Research Organizations (CROs), patient advocacy groups and healthtech companies. As an enterprise offering, it enables teams to screen patient populations in bulk and integrates seamlessly with existing EHRs and industry workflows, further streamlining operations and accelerating trial recruitment.

"At myTomorrows, we're purpose-driven, committed to serving and connecting all stakeholders across the care continuum and pre-approval journey. Built for pre-screening at scale, our technology will unlock immense efficiency gains while ensuring more qualified patients gain timely access to trials," continued Dr. van Harten.

Physicians interested in experiencing the new precision technology first-hand can secure their spot here and enterprises interested in applying for beta access can register here.

About myTomorrows:

myTomorrows is a global healthtech company dedicated to breaking down barriers for patients seeking treatment options. To make this a reality, the company has built a unique and powerful proprietary technology that conducts a comprehensive and accurate search of clinical trials databases worldwide, efficiently connecting patients, physicians, trial sites and BioPharma to simplify and accelerate access to drugs in development. Headquartered in Amsterdam with an office in New York City, myTomorrows has helped more than 14,000 patients and 2,200 physicians across 200+ sites in over 125 countries.

www.mytomorrows.com.

myTomorrows Media Contact:

Ben Crome
Headline Media
[email protected]
+1 914 336 4922

SOURCE myTomorrows